Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

Rheumatoid Arthritis

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Ann Rheum Dis

Schaefer M, Purschke A, Zietemann V, Rudi T, Meissner Y, Richter A, Berger S, Rockwitz K, Krüger K, Schneider KM, Regierer AC, Strangfeld A

doi: 10.1016/j.ard.2025.05.014

Systemic Lupus Erythematosus

Effects of sodium-glucose transporter 2 inhibitors in patients with lupus nephritis: a before-and-after retrospective cohort study

Rheumatology (Oxford)

Ramírez-Mulhern I, Navarro-Sánchez V, Rivero-Otamendi E, Sánchez-Mejía DE, Zavala-Miranda MF, Mejia-Vilet JM

doi: 10.1093/rheumatology/keaf548

Rheumatoid Arthritis

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Arthritis Rheumatol

Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K

doi: 10.1002/art.43188

Rheumatoid Arthritis

Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort

Ann Rheum Dis

Frazzei G, Landewé RBM, Wagenaar C, van de Stadt LA, van Schaardenburg D, Tas SW, van Vollenhoven RF

doi: 10.1016/j.ard.2025.01.042

Rheumatoid Arthritis

EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia

Ann Rheum Dis

van Steenbergen HW, Doornkamp F, Alivernini S, Backlund J, Codreanu C, Cohen SB, Combe B, Cope AP, Deane KD, England BR, Falahee M, de Jong PHP, Kleyer A, Lacaille D, Maat B, Mankia K, van Mulligen E, Nagy G, O'Neil LJ, Rodamaker L, Sahbudin I, van Schaardenburg D, Sepriano A, da Silva JAP, De Smet L, Sparks JA, Steyerberg EW, Studenic P, Wethington E, Landewé RL, Raza K, van der Helm-van Mil AHM

doi: 10.1016/j.ard.2025.01.021

Rheumatoid Arthritis

Frailty carries an increased risk of death in rheumatoid arthritis

Semin Arthritis Rheum

Bhide SA, Roul P, England BR, Brubeck HF, Cannon GW, Singh N, Loecker C, Kunkel G, Mikuls TR, Shoback DM, Michaud K, Katz PP, Garcia JM, Orkaby AR, Baker JF, Wysham KD

doi: 10.1016/j.semarthrit.2025.152872

Rheumatoid Arthritis

Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis

Arthritis Care Res (Hoboken)

Kawano Y, Weber BN, Weisenfeld D, Jeffway MI, Cai T, McDermott GC, Liu Q, Sparks JA, Stuart J, Joseph J, Cai T, Liao KP

doi: 10.1002/acr.25481

Psoriatic Arthritis

Diagnostic delay and less intensive therapy for people with psoriatic arthritis compared with rheumatoid arthritis: a study nested within an English and Welsh audit data set

Ann Rheum Dis

Charlton RA, Gates E, Coates LC, Galloway J, McHugh N, McGrogan A, Hackett S, Brooke M, Cavill C, Tillett W

doi: 10.1016/j.ard.2025.02.020

Rheumatoid Arthritis

Gastrointestinal perforation as a safety concern among patients with rheumatoid arthritis on Janus kinase inhibitor therapy: A systematic review and network meta-analysis

Arthritis Care Res (Hoboken)

Sathapanasiri T, Meraz M, Mokri H, Veettil S, Wijarnpreecha K, Schlesinger N, Kavanaugh A, Chaiyakunapruk N

doi: 10.1002/acr.25554

Related content

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Effects of sodium-glucose transporter 2 inhibitors in patients with lupus nephritis: a before-and-after retrospective cohort study

Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries (the "JAK-pot" study)

Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort

EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia

Frailty carries an increased risk of death in rheumatoid arthritis

Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis

Diagnostic delay and less intensive therapy for people with psoriatic arthritis compared with rheumatoid arthritis: a study nested within an English and Welsh audit data set

Gastrointestinal perforation as a safety concern among patients with rheumatoid arthritis on Janus kinase inhibitor therapy: A systematic review and network meta-analysis